VivaGel well tolerated: Starpharma
Monday, 12 May, 2008
Melbourne biotech Starpharma has released positive results of a clinical trial for its topical microbicide VivaGel.
The double-blind trial of 54 women in the US and Kenya demonstrated that VivaGel was safe and well-tolerated in sexually abstinent women.
It means the product has been deemed suitable for continued development as a topical microbicide for the prevention of HIV and genital herpes. Starpharma is also investigating its efficacy in human papillomavirus (HPV).
The clinical study was funded by the US Division of Microbiology and Infectious Diseases (DMID), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) and conducted by DMID in collaboration with the Sexually Transmitted Infections Clinical Trials Group (STI-CTG).
It was the first study to be conducted under the US Investigational New Drug application (IND) for VivaGel for prevention of genital herpes.
For more information on Starpharma and VivaGel, see the May/June issue of ALS.
Liquid fat treatment provides hope for rare childhood disease
A liquid fat supplement, triheptanoin, can reverse mitochondrial dysfunction and cell death in...
NSW Govt delivers foot-and-mouth vaccine to protect livestock
A biodegradable vaccine to protect livestock from foot-and-mouth disease has been developed as...
Scientists optimise delivery of mRNA to target cells
A highly versatile new method captures and attaches antibodies to the surface of mRNA-loaded...
